AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Scientists have identified HER2/neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
"HRE2/neu-specific cellular and humoral immune responses are often detected in breast cancer patients, but identification of more immunogenic CTL epitope peptides is necessary prior to development of a cancer vaccine. There is accumulating evidence of strong immunogenicity of peptides capable of inducing both cellular and humoral immune responses. To identify such peptides, this study intended to determine HER2/neu-derived peptides capable of inducing both cellular and humoral immunity in HLA-A24+ breast cancer patients," investigators in Japan report.
"IgGs reactive to the HER2[subscript]342-350, HER2[subscript]485-493, and HER2[subscript]553-561 peptides were detected in the sera of these patients with the frequency of 47, 24, and 24%, respectively," said Koichi Azuma and colleagues at Kurume University. "These peptides also induced peptide-specific and tumor-reactive CTL activity in the peripheral blood mononuclear cells of HLA-A24+ breast cancer patients with the frequency of 50, 63, and 25%, respectively, but such activity was not induced from any HLA-A24- patients. Cellular and humoral responses to each ...